Drugs / ATR12-351
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06137157 | Jun 2024 → Jun 2026 overdue | Netherton syndrome | Azitra Inc. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATR12-351 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06137157 ↗ |
| Action | Restore | “ATR12-351 is intended to address the underlying cause of NS by replacing deficient/dysfunctional LEKTI.” NCT06137157 ↗ |
| Modality | Other / unclassified | “a live biotherapeutic product (LBP)” NCT06137157 ↗ |
| Route | Topical | “ATR12-351 is a topical ointment” NCT06137157 ↗ |